The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The promise of GLP-1 receptor agonists for the prevention of acute leukemias in high-risk patients
In this video, Colton Jones, MD, University of Texas San Antonio, San Antonio, TX, discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists for the prevention of acute leukemias. Dr Jones notes that his research group’s study found a significant risk reduction in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in high-risk patients, including those with prior chemotherapy or genetic predisposition. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
